Pharmaceutical Specialties, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pharmaceutical Specialties, Inc. - overview
Established
1995
Location
-, GA, US
Primary Industry
Pharmaceuticals
About
Pharmaceutical Specialties, Inc. is a provider of specialty pharmacy services that focuses on delivering tailored healthcare solutions for patients with complex medical needs, particularly in the areas of rare diseases and chronic conditions. Founded in 1995 in the United States, Pharmaceutical Specialties, Inc. specializes in providing pharmacy services aimed at rare diseases.
The company was acquired by Maxor National Pharmacy Services, LLC in September 2016, with the deal finalized in December 2016. Pharmaceutical Specialties, Inc. operates under the name VytlOne, offering a comprehensive range of specialty and infusion pharmacy services. Their portfolio includes limited distribution medications for complex conditions, such as Trikafta®, Kalydeco®, and Orkambi®.
By collaborating with healthcare providers, they create customized treatment plans that enhance patient adherence and support, ultimately improving health outcomes. The revenue model of Pharmaceutical Specialties, Inc. is based on its specialty pharmacy services, which encompass both direct-to-consumer and business-to-business transactions. Revenue is generated through the dispensing of specialty medications and associated services, reflecting the company's strategic partnerships in the healthcare ecosystem.
Pharmaceutical Specialties, Inc. plans to leverage its recent acquisition by Maxor National Pharmacy Services to expand its product offerings and market reach. The firm aims to enhance its portfolio with new specialty medications tailored for rare diseases, focusing on launching these products by the end of 2023. Additionally, the company is targeting expansion into new geographic markets across the United States to broaden its service delivery by 2024.
The acquisition funding will support these initiatives, facilitating further growth and enhancing patient care capabilities.
Current Investors
Maxor National Pharmacy Services, LLC
Primary Industry
Pharmaceuticals
Sub Industries
Drug Stores/Convenience Stores, Healthcare, Specialty Pharmaceuticals
Website
http://www.psipharmacy.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Pharmaceutical Specialties, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Pharmaceutical Specialties, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.